Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 389

1.

Balancing benefits and risks in the era of biologics.

Adami G, Saag KG, Chapurlat RD, Guañabens N, Haugeberg G, Lems WF, Matijevic R, Peel N, Poddubnyy D, Geusens P.

Ther Adv Musculoskelet Dis. 2019 Oct 24;11:1759720X19883973. doi: 10.1177/1759720X19883973. eCollection 2019. Review.

2.

Secondary fracture prevention: Drug treatment, fall prevention and nutrition requirements.

Geusens P, Lems WF, Bours S, Vd Bergh JP.

Best Pract Res Clin Rheumatol. 2019 Apr;33(2):290-300. doi: 10.1016/j.berh.2019.04.005. Epub 2019 May 13. Review.

PMID:
31547984
3.

Pharmacological Management of Osteoporosis in Rheumatoid Arthritis Patients: A Review of the Literature and Practical Guide.

Raterman HG, Lems WF.

Drugs Aging. 2019 Sep 21. doi: 10.1007/s40266-019-00714-4. [Epub ahead of print]

PMID:
31541358
4.

Osteoarthritis and intervertebral disc degeneration: Quite different, quite similar.

Rustenburg CME, Emanuel KS, Peeters M, Lems WF, Vergroesen PA, Smit TH.

JOR Spine. 2018 Oct 19;1(4):e1033. doi: 10.1002/jsp2.1033. eCollection 2018 Dec. Review.

5.

Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.

van Maren MA, Wyers CE, Driessen JHM, Visser JV, de Vries F, van de Wijdeven K, Gevers S, Lems WF, Emmelot-Vonk MH, van den Bergh JPW.

Osteoporos Int. 2019 Sep;30(9):1837-1844. doi: 10.1007/s00198-019-05052-0. Epub 2019 Jul 18.

6.

Reply.

Saag KG, Geusens P, Lems WF.

Arthritis Rheumatol. 2019 Oct;71(10):1771-1772. doi: 10.1002/art.41013. Epub 2019 Sep 2. No abstract available.

PMID:
31215773
7.

Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme.

Heslinga M, Van Den Oever I, Jonker DL, Griep EN, Griep-Wentink H, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters M, Van Schaardenburg D, Nurmohamed MT.

Scand J Rheumatol. 2019 Sep;48(5):345-352. doi: 10.1080/03009742.2019.1600718. Epub 2019 Jun 18.

PMID:
31210083
8.

Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis.

Raterman HG, Bultink IEM, Lems WF.

Drugs. 2019 Jul;79(10):1065-1087. doi: 10.1007/s40265-019-01145-6. Review.

PMID:
31201710
9.

Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis.

Blomjous BS, Boers M, Den Uyl D, Twisk J, Van Schaardenburg D, Voskuyl AE, Lems WF, Ter Wee MM.

Scand J Rheumatol. 2019 Jul;48(4):271-278. doi: 10.1080/03009742.2019.1570549. Epub 2019 May 28.

PMID:
31135239
10.

Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial.

Hartman L, Bos R, Buttgereit F, Güler-Yuksel M, Ionescu R, Kok MR, Lems WF, Micaelo M, Opris-Belinski D, Pusztai A, Santos E, Da Silva J, Szekanecz Z, Zeiner K, Zhang D, Boers M.

Scand J Rheumatol. 2019 Jul;48(4):340-341. doi: 10.1080/03009742.2018.1559880. Epub 2019 May 27. No abstract available.

PMID:
31132016
11.

Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study.

Agca R, Hopman LHGA, Laan KJC, van Halm VP, Peters MJL, Smulders YM, Dekker JM, Nijpels G, Stehouwer CDA, Voskuyl AE, Boers M, Lems WF, Nurmohamed MT.

J Rheumatol. 2019 May 15. pii: jrheum.180726. doi: 10.3899/jrheum.180726. [Epub ahead of print]

PMID:
31092721
12.

Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis.

de Jong TD, Snoek T, Mantel E, van der Laken CJ, van Vollenhoven RF, Lems WF.

Front Immunol. 2019 Apr 24;10:902. doi: 10.3389/fimmu.2019.00902. eCollection 2019.

13.

Development and Validation of a Sensitive UHPLC-MS/MS-Based Method for the Analysis of Folylpolyglutamate Synthetase Enzymatic Activity in Peripheral Blood Mononuclear Cells: Application in Rheumatoid Arthritis and Leukemia Patients.

Muller IB, Lin M, Struys EA, Heydari P, Hebing RCF, Nurmohamed MT, van der Laken C, Lems WF, Cloos J, Jansen G, de Jonge R.

Ther Drug Monit. 2019 Oct;41(5):598-606. doi: 10.1097/FTD.0000000000000638.

PMID:
31008996
14.

Is a model of stratified exercise therapy by physical therapists in primary care feasible in patients with knee osteoarthritis? : a mixed methods study.

Knoop J, van der Leeden M, van der Esch M, de Rooij M, Peter WF, Bennell KL, Steultjens MPM, Hakkinen A, Roorda LD, Lems WF, Dekker J.

Physiotherapy. 2019 Jan 26. pii: S0031-9406(19)30033-1. doi: 10.1016/j.physio.2019.01.013. [Epub ahead of print]

PMID:
30981515
15.

Pain, sleep and emotional well-being explain the lack of agreement between physician- and patient-perceived remission in early rheumatoid arthritis.

Turk SA, Rasch LA, van Schaardenburg D, Lems WF, Sanberg M, van Tuyl LHD, Ter Wee MM.

BMC Rheumatol. 2018 Jun 26;2:16. doi: 10.1186/s41927-018-0024-9. eCollection 2018.

16.

Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.

Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.

Arthritis Rheumatol. 2019 Jul;71(7):1174-1184. doi: 10.1002/art.40874. Epub 2019 May 25.

17.

Change in cardiovascular risk after initiation of anti-rheumatic treatment in early rheumatoid arthritis.

Turk SA, Heslinga M, Twisk J, van der Lugt V, Lems WF, van Schaardenburg D, Nurmohamed MT.

Clin Exp Rheumatol. 2019 May-Jun;37(3):513. Epub 2019 Feb 15. No abstract available.

18.

Long-Term Treatment With TNF-Alpha Inhibitors Improves Bone Mineral Density But Not Vertebral Fracture Progression in Ankylosing Spondylitis.

Beek KJ, Rusman T, van der Weijden MAC, Lems WF, van Denderen JC, Konsta M, Visman I, Nurmohamed MT, van der Horst-Bruinsma IE.

J Bone Miner Res. 2019 Jun;34(6):1041-1048. doi: 10.1002/jbmr.3684. Epub 2019 Mar 25.

PMID:
30690799
19.

Common mechanisms and holistic care in atherosclerosis and osteoporosis.

Szekanecz Z, Raterman HG, Pethő Z, Lems WF.

Arthritis Res Ther. 2019 Jan 10;21(1):15. doi: 10.1186/s13075-018-1805-7. Review.

20.

Patients' preferences for osteoarthritis treatment: the value of stated-preference studies.

Hiligsmann M, Pinto D, Dennison E, Al-Daghri N, Beaudart C, Branco J, Bruyère O, Conaghan PG, Cooper C, Herrero-Beaumont G, Jiwa F, Lems W, Rizzoli R, Thomas T, Veronese N, Reginster JY.

Aging Clin Exp Res. 2019 Jan;31(1):1-3. doi: 10.1007/s40520-018-1098-3. Epub 2019 Jan 4. No abstract available.

21.

Dietary protein intake and upper leg muscle strength in subjects with knee osteoarthritis: data from the osteoarthritis initiative.

de Zwart AH, van der Leeden M, Roorda LD, Visser M, van der Esch M, Lems WF, Dekker J.

Rheumatol Int. 2019 Feb;39(2):277-284. doi: 10.1007/s00296-018-4223-x. Epub 2019 Jan 2.

PMID:
30600342
22.

Response to: 'Knee osteoarthritis and bisphosphonates: Could BCP crystals be the missing link?' by Murphy et al.

Lems W.

Ann Rheum Dis. 2019 Dec;78(12):e142. doi: 10.1136/annrheumdis-2018-214493. Epub 2018 Nov 2. No abstract available.

PMID:
30389691
23.

Outcome measures for adherence data from a medication event monitoring system: A literature review.

Hartman L, Lems WF, Boers M.

J Clin Pharm Ther. 2019 Feb;44(1):1-5. doi: 10.1111/jcpt.12757. Epub 2018 Sep 1. Review.

PMID:
30171815
24.

Decreased Pain and Improved Dynamic Knee Instability Mediate the Beneficial Effect of Wearing a Soft Knee Brace on Activity Limitations in Patients With Knee Osteoarthritis.

Cudejko T, van der Esch M, van den Noort JC, Rijnhart JJM, van der Leeden M, Roorda LD, Lems W, Waddington G, Harlaar J, Dekker J.

Arthritis Care Res (Hoboken). 2019 Aug;71(8):1036-1043. doi: 10.1002/acr.23722. Epub 2019 Jul 12.

25.

The immediate effect of a soft knee brace on dynamic knee instability in persons with knee osteoarthritis.

Cudejko T, van der Esch M, Schrijvers J, Richards R, van den Noort JC, Wrigley T, van der Leeden M, Roorda LD, Lems W, Harlaar J, Dekker J.

Rheumatology (Oxford). 2018 Oct 1;57(10):1735-1742. doi: 10.1093/rheumatology/key162.

PMID:
29931372
26.

Clinical utility of bone markers in various diseases.

Vlot MC, den Heijer M, de Jongh RT, Vervloet MG, Lems WF, de Jonge R, Obermayer-Pietsch B, Heijboer AC.

Bone. 2018 Sep;114:215-225. doi: 10.1016/j.bone.2018.06.011. Epub 2018 Jun 18. Review.

PMID:
29920402
27.

Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis.

Akdemir G, Markusse IM, Bergstra SA, Goekoop RJ, Molenaar ET, van Groenendael JHLM, Kerstens PJSM, Lems WF, Huizinga TWJ, Allaart CF.

RMD Open. 2018 May 20;4(1):e000649. doi: 10.1136/rmdopen-2018-000649. eCollection 2018.

28.

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake TRDJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018.

29.

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.

Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, McColl G, Ten Klooster PM, Zijlstra TR, Lems WF, Riyazi N, Griep EN, Hazes JMW, Landewé R, Bernelot Moens HJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2018 Oct;70(10):1557-1564. doi: 10.1002/art.40546. Epub 2018 Aug 23.

30.

Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.

Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R, Chapurlat R, Wang A, Pannacciulli N, Lems WF.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5. Epub 2018 Apr 6.

PMID:
29631782
31.

An unfavorable body composition is common in early arthritis patients: A case control study.

Turk SA, van Schaardenburg D, Boers M, de Boer S, Fokker C, Lems WF, Nurmohamed MT.

PLoS One. 2018 Mar 22;13(3):e0193377. doi: 10.1371/journal.pone.0193377. eCollection 2018.

32.

TNF inhibitor treatment is associated with a lower risk of hand osteoarthritis progression in rheumatoid arthritis patients after 10 years.

Loef M, Kroon FPB, Bergstra SA, van der Pol JA, Lems WF, Kerstens PJSM, Allaart CF, Kloppenburg M.

Rheumatology (Oxford). 2018 Nov 1;57(11):1917-1924. doi: 10.1093/rheumatology/key016.

PMID:
29471377
33.

Clinically relevant discrepancies between different rheumatoid factor assays.

Falkenburg WJJ, von Richthofen HJ, Koers J, Weykamp C, Schreurs MWJ, Bakker-Jonges LE, Haagen IA, Lems WF, Hamann D, van Schaardenburg D, Rispens T.

Clin Chem Lab Med. 2018 Sep 25;56(10):1749-1758. doi: 10.1515/cclm-2017-0988. No abstract available.

34.

Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.

Hartman L, Rasch LA, Klausch T, Bijlsma HWJ, Christensen R, Smulders YM, Ralston SH, Buttgereit F, Cutolo M, Da Silva JAP, Opris D, Rovenský J, Szamosi S, Middelink LM, Lems WF, Boers M.

Trials. 2018 Jan 25;19(1):67. doi: 10.1186/s13063-017-2396-3.

35.

Glucocorticoids, Inflammation and Bone.

Güler-Yüksel M, Hoes JN, Bultink IEM, Lems WF.

Calcif Tissue Int. 2018 May;102(5):592-606. doi: 10.1007/s00223-017-0335-7. Epub 2018 Jan 8. Review.

PMID:
29313071
36.

Bisphosphonates: a therapeutic option for knee osteoarthritis?

Lems WF.

Ann Rheum Dis. 2018 Sep;77(9):1247-1248. doi: 10.1136/annrheumdis-2017-212364. Epub 2017 Dec 13. No abstract available.

PMID:
29237617
37.

Critical issues and current challenges in osteoporosis and fracture prevention. An overview of unmet needs.

Lems WF, Raterman HG.

Ther Adv Musculoskelet Dis. 2017 Dec;9(12):299-316. doi: 10.1177/1759720X17732562. Epub 2017 Oct 27. Review.

38.

The immediate effect of a soft knee brace on pain, activity limitations, self-reported knee instability, and self-reported knee confidence in patients with knee osteoarthritis.

Cudejko T, van der Esch M, van der Leeden M, van den Noort JC, Roorda LD, Lems W, Twisk J, Steultjens M, Woodburn J, Harlaar J, Dekker J.

Arthritis Res Ther. 2017 Dec 1;19(1):260. doi: 10.1186/s13075-017-1456-0.

39.

Factors associated with upper leg muscle strength in knee osteoarthritis: A scoping review.

de Zwart AH, Dekker J, Lems W, Roorda LD, van der Esch M, van der Leeden M.

J Rehabil Med. 2018 Feb 13;50(2):140-150. doi: 10.2340/16501977-2284. Review.

40.

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.

Ter Wee MM, Coupé VM, den Uyl D, Blomjous BS, Kooijmans E, Kerstens PJ, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Boers M, Lems WF.

RMD Open. 2017 Oct 25;3(2):e000502. doi: 10.1136/rmdopen-2017-000502. eCollection 2017.

41.

Proprioception mediates the association between systemic inflammation and muscle weakness in patients with knee osteoarthritis: Results from the Amsterdam Osteoarthritis cohort.

Cudejko T, van der Esch M, van der Leeden M, Holla J, Roorda LD, Lems W, Dekker J.

J Rehabil Med. 2018 Jan 10;50(1):67-72. doi: 10.2340/16501977-2272.

42.

What have we learned from BeSt?

Allaart CF, Markusse IM, Lems WF.

Clin Immunol. 2018 Jan;186:74-78. doi: 10.1016/j.clim.2017.09.017. Epub 2017 Sep 18.

43.

Inflammatory diseases and bone fragility.

Briot K, Geusens P, Em Bultink I, Lems WF, Roux C.

Osteoporos Int. 2017 Dec;28(12):3301-3314. doi: 10.1007/s00198-017-4189-7. Epub 2017 Sep 15. Review.

PMID:
28916915
44.

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Rheumatology (Oxford). 2017 Sep 1;56(9):1586-1596. doi: 10.1093/rheumatology/kex223.

PMID:
28859326
45.

Analgesic use in patients with knee and/or hip osteoarthritis referred to an outpatient center: a cross-sectional study within the Amsterdam Osteoarthritis Cohort.

Knoop J, van Tunen J, van der Esch M, Roorda LD, Dekker J, van der Leeden M, Lems WF.

Rheumatol Int. 2017 Oct;37(10):1747-1755. doi: 10.1007/s00296-017-3785-3. Epub 2017 Aug 18.

PMID:
28821939
46.

Effect of implementation of guidelines on assessment and diagnosis of vertebral fractures in patients older than 50 years with a recent non-vertebral fracture.

van der Velde RY, Bours SPG, Wyers CE, Lems WF, Geusens PPMM, van den Bergh JPW.

Osteoporos Int. 2017 Oct;28(10):3017-3022. doi: 10.1007/s00198-017-4147-4. Epub 2017 Jul 26.

47.

Fat Mass Lowers the Response to Tumor Necrosis Factor-α Blockers in Patients with Ankylosing Spondylitis.

Ibáñez Vodnizza SE, Nurmohamed MT, Visman IM, van Denderen JC, Lems WF, Jaime F, van der Horst-Bruinsma IE.

J Rheumatol. 2017 Sep;44(9):1355-1361. doi: 10.3899/jrheum.170094. Epub 2017 Jul 15.

PMID:
28711878
48.

Nonlinear relationship between isokinetic muscle strength and activity limitations in patients with knee osteoarthritis: Results of the Amsterdam-Osteoarthritis cohort.

Edelaar LM, van Dieën JH, van der Esch M, Roorda LD, Dekker J, Lems WF, van der Leeden M.

J Rehabil Med. 2017 Jul 7;49(7):598-605. doi: 10.2340/16501977-2252.

49.

Muscle wasting in male TNF-α blocker naïve ankylosing spondylitis patients: a comparison of gender differences in body composition.

Ibáñez Vodnizza S, Visman IM, van Denderen C, Lems WF, Jaime F, Nurmohamed MT, van der Horst-Bruinsma IE.

Rheumatology (Oxford). 2017 Sep 1;56(9):1566-1572. doi: 10.1093/rheumatology/kex187.

PMID:
28605535
50.

Is Fragility Fracture a Strong Risk Factor for a Cardiovascular Event in Rheumatoid Arthritis? The Challenge of Dealing with Multiple Comorbidities.

Lems WF.

J Rheumatol. 2017 May;44(5):545-546. doi: 10.3899/jrheum.170202. No abstract available.

PMID:
28461515

Supplemental Content

Support Center